மையம் இல் வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Baricitinib reduces mortality of hospitalised COVID patients by almost half
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Lilly and Incyte s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
FDA broadens existing emergency use of Lilly and Incyte s baricitinib in patients hospitalized with COVID-19 requiring oxygen
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(0)
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte (INCY) on Thursday said their late-stage study of baricitinib in hospitalized Covid-19 patients did not achieve the main goal.
The phase III study dubbed Cov-Barrier of baricitinib plus standard of care (SoC) versus placebo plus SoC did not meet statistical significance on the primary endpoint. The main goal was defined as the difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28.
The frequency of adverse events and serious adverse events were generally similar in the baricitinib and placebo groups, Eli Lilly said.
Share this article
Share this article
INDIANAPOLIS, April 8, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28. Baricitinib-treated patients were 2.7 percent less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death, a difference that was not statistically significant (odds ratio [OR]: 0.85; 95% CI 0.67, 1.08; p=0.1800).